

October 6, 2021



## **Zivo Bioscience, Inc. to Participate in the Global AgTech Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on October 14, 2021 at 10 A.M. EDT**

KEEGO HARBOR, Mich., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) ("ZIVO" and the "Company"), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, announced today that Company CEO Andrew A. Dahl has been invited to present at the Global AgTech Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on October 14, 2021 at 10 a.m. EDT.

Andrew A. Dahl will be presenting during the panel titled "The Health and Wellness Panel".

The event will consist of four virtual panels with executive management from multiple companies in the AgTech sector and of keynote speaker Ambassador Kip E. Tom, the Chief Executive Officer of Leesburg-based Tom Farms, which grows corn, soybeans, and seed corn in seven northern Indiana counties and is among Indiana's largest farming operations.

The panel discussions will be moderated by Anthony Vendetti, Maxim's Executive Director of Research & Senior Analyst.

This conference will be live on M-Vest. To attend, just sign up to become an M-Vest member.

[Click Here to Reserve your seat](#)

### **About Zivo Bioscience, Inc.**

Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a Michigan-based biotech/agtech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on the general benefits of autoimmune and inflammatory response modulation. Visit [zivobioscience.com](http://zivobioscience.com) to learn more.

## **Forward Looking Statements**

Except for any historical information, the matters discussed herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and ZIVO undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.

### **Contacts:**

#### **Investor Relations**

CORE IR

516-222-2560

[Investor@zivobioscience.com](mailto:Investor@zivobioscience.com)

#### **Media**

CORE IR

Jules Abraham

917-885-7378

[julesa@coreir.com](mailto:julesa@coreir.com)

Source: Zivo Bioscience, Inc.



Source: Zivo Bioscience, Inc.